Clinical trial

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

NCT04158856

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2020-06-01

PhasePHASE2

Study timeline

Study start (estimated)2020-06-01Date precision: day

Registry last updated2019-11-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HER2-positive Breast Cancerunresolved

Interventions

PyrotinibDRUG

TrastuzumabDRUG · verified · RxNorm: trastuzumab

Sponsors & collaborators

xuexin helead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04158856 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.